Alembic Pharmaceuticals is currently trading at Rs. 556.85, up by 2.00 points or 0.36% from its previous closing of Rs. 554.85 on the BSE.
The scrip opened at Rs. 555.55 and has touched a high and low of Rs. 560.00 and Rs. 554.85 respectively. So far 215 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 598.00 on 27-Jul-2018 and a 52 week low of Rs. 412.40 on 24-May-2018.
Last one week high and low of the scrip stood at Rs. 598.00 and Rs. 545.80 respectively. The current market cap of the company is Rs. 10487.14 crore.
The promoters holding in the company stood at 72.96%, while Institutions and Non-Institutions held 14.30% and 12.74% respectively.
Alembic Pharmaceuticals has reported over 2-fold jump in its net profit at Rs 113.98 crore for first quarter ended June 30, 2018, as compared to net profit of Rs 50.67 crore for the same quarter in the previous year. Total income of the company increased by 37.48% at Rs 811.58 crore for Q1FY19 as compared Rs 590.34 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a rise of 35.70% in its net profit at Rs 90.47 crore for the quarter under review as compared to Rs 66.67 crore for the same quarter in the previous year. Total consolidated income of the company increased by 33.05% at Rs 862.63 crore for Q1FY19 as compared Rs 648.36 crore for the corresponding quarter previous year.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1462.50 |
Dr. Reddys Lab | 5784.50 |
Cipla | 1451.25 |
Zydus Lifesciences | 1001.15 |
Lupin | 1587.90 |
View more.. |